Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

26.32
+1.335.32%
Post-market: 26.350.0300+0.11%19:59 EST
Volume:18.35M
Turnover:480.95M
Market Cap:30.20B
PE:42.65
High:26.45
Open:25.90
Low:25.74
Close:24.99
52wk High:26.45
52wk Low:12.47
Shares:1.15B
Float Shares:1.14B
Volume Ratio:2.08
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6171
EPS(LYR):-1.4492
ROE:9.71%
ROA:5.45%
PB:4.17
PE(LYR):-18.16

Loading ...

Nov 26, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 20, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 14, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 05, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 05, 2025

Major Issues Report

Form 8-K - Current report
Sep 12, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 02, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 01, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 30, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 30, 2025

Major Issues Report

Form 8-K - Current report
Jun 13, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 05, 2025

Major Issues Report

Form 8-K - Current report
Jun 03, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 28, 2025

Major Issues Report

Form 8-K - Current report
May 22, 2025

Major Issues Report

Form 8-K - Current report
May 20, 2025

[Supp]Public Prospectus

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
May 08, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 08, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 07, 2025

Major Issues Report

Form 8-K - Current report
Apr 15, 2025

Correspondence

Form CORRESP - Correspondence